Keeping an ‘eye’ on ocular GVHD

References

• Hill GR, Betts BC, Tkachev V, et al. Current concepts and advances in graft-versus-host disease immunology. Annu Rev Immunol. 2021;39:19–49.
   Web of Science ®Google Scholar
• Styczyński J, Tridello G, Koster L, et al. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transplant. 2020;55:126–136.
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: i. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–956.
   PubMed Web of Science ®Google Scholar
• Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117:3214–3219.
   PubMed Web of Science ®Google Scholar
• Jagasia MH, Greinix HT, Arora M, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: i. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21:389–401.e381.
   PubMed Web of Science ®Google Scholar
• Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98:2043–2051.
   PubMed Web of Science ®Google Scholar
• Petersdorf EW. Which factors influence the development of GVHD in HLA-matched or mismatched transplants? Best Pract Res Clin Haematol. 2017;30:333–335.
   Web of Science ®Google Scholar
• Fürst D, Neuchel C, Tsamadou C, et al. HLA matching in unrelated stem cell transplantation up to date. Transfus Med Hemother. 2019;46:326–336.
   Web of Science ®Google Scholar
• Inamoto Y, Valdés-Sanz N, Ogawa Y, et al. ocular graft-versus-host disease after hematopoietic cell transplantation: expert review from the late effects and quality of life working committee of the center for international blood and marrow transplant research and transplant complications working party of the european society of blood and marrow transplantation. Biol Blood Marrow Transplant. 2019;25:e46–e54.
   PubMedGoogle Scholar
• Munir SZ, Aylward J. A review of ocular graft-versus-host disease. Optom Vis Sci. 2017;94:545–555.
   PubMed Web of Science ®Google Scholar
• Anderson NG, Regillo C. Ocular manifestations of graft versus host disease. Curr Opin Ophthalmol. 2004;15:503–507.
   PubMedGoogle Scholar
• Jacobs R, Tran U, Chen H, et al. Prevalence and risk factors associated with development of ocular GVHD defined by NIH consensus criteria. Bone Marrow Transplant. 2012;47:1470–1473.
   PubMed Web of Science ®Google Scholar
• Na KS, Yoo YS, Mok JW, et al. Incidence and risk factors for ocular GVHD after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2015;50:1459–1464.
   PubMedGoogle Scholar
• Uchino M, Ogawa Y, Uchino Y, et al. Comparison of stem cell sources in the severity of dry eye after allogeneic haematopoietic stem cell transplantation. Br J Ophthalmol. 2012;96:34–37.
   Web of Science ®Google Scholar
• Kamoi M, Ogawa Y, Uchino M, et al. Donor-recipient gender difference affects severity of dry eye after hematopoietic stem cell transplantation. Eye (Lond). 2011;25:860–865.
   Web of Science ®Google Scholar
• Wang JC, Teichman JC, Mustafa M, et al. Risk factors for the development of ocular graft-versus-host disease (GVHD) dry eye syndrome in patients with chronic GVHD. Br J Ophthalmol. 2015;99:1514–1518.
   PubMed Web of Science ®Google Scholar
• Balaram M, Dana MR. Phacoemulsification in patients after allogeneic bone marrow transplantation. Ophthalmology. 2001;108:1682–1687.
   Web of Science ®Google Scholar
• Qiu Y, Hong J, Peng R. Manifestation of clinical categories of ocular graft-versus-host disease. J Ophthalmol. 2018;2018:6430953.
   Web of Science ®Google Scholar
• Dietrich-Ntoukas T, Cursiefen C, Westekemper H, et al. Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD. Cornea. 2012;31:299–310.
   PubMed Web of Science ®Google Scholar
• Rojas B, Cuhna R, Zafirakis P, et al. Cell populations and adhesion molecules expression in conjunctiva before and after bone marrow transplantation. Exp Eye Res. 2005;81:313–325.
   PubMed Web of Science ®Google Scholar
• Allan EJ, Flowers ME, Lin MP, et al. Visual acuity and anterior segment findings in chronic graft-versus-host disease. Cornea. 2011;30:1392–1397.
   PubMed Web of Science ®Google Scholar
• Giannaccare G, Pellegrini M, Bernabei F, et al. Ocular surface system alterations in ocular graft-versus-host disease: all the pieces of the complex puzzle. Graefes Arch Clin Exp Ophthalmol. 2019;257:1341–1351.
   PubMed Web of Science ®Google Scholar
• Hwang HS, Ha M, Kim HS, et al. Longitudinal analysis of meibomian gland dropout in patients with ocular graft-versus-host disease. Ocul Surf. 2019;17:464–469.
   PubMed Web of Science ®Google Scholar
• Dikmetas O, Kocabeyoglu S, Mocan MC. The association between meibomian gland atrophy and corneal subbasal nerve loss in patients with chronic ocular graft-versus-host disease. Curr Eye Res. 2021;46(6):796–801.
   Web of Science ®Google Scholar
• Hassan AS, Clouthier SG, Ferrara JL, et al. Lacrimal gland involvement in graft-versus-host disease: a murine model. Invest Ophthalmol Vis Sci. 2005;46:2692–2697.
   Web of Science ®Google Scholar
• Kim S, Yoo YS, Kim HS, et al. Changes of meibomian glands in the early stage of post hematopoietic stem cell transplantation. Exp Eye Res. 2017;163:85–90.
   PubMed Web of Science ®Google Scholar
• Kusne Y, Temkit M, Khera N, et al. Conjunctival subepithelial fibrosis and meibomian gland atrophy in ocular graft-versus-host disease. Ocul Surf. 2017;15:784–788.
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Kim SK, Dana R, et al. International chronic ocular graft-vs-host-disease (GVHD) consensus group: proposed diagnostic criteria for chronic GVHD (Part I). Sci Rep. 2013;3:3419.
   PubMed Web of Science ®Google Scholar
• Rapoport Y, Freeman T, Koyama T, et al. Validation of International chronic ocular graft-versus-host disease (GVHD) group diagnostic criteria as a chronic ocular GVHD-specific metric. Cornea. 2017;36:258–263.
   PubMed Web of Science ®Google Scholar
• Schargus M, Meyer-ter-vehn T, Menrath J, et al. correlation between tear film osmolarity and the disease score of the international chronic ocular graft-versus-host-disease consensus group in hematopoietic stem cell transplantation patients. Cornea. 2015;34:911–916.
   Web of Science ®Google Scholar
• Shikari H, Antin JH, Dana R. Ocular graft-versus-host disease: a review. Surv Ophthalmol. 2013;58:233–251.
   PubMed Web of Science ®Google Scholar
• Hosseini H, Kumar PV, Geramizadeh B, et al. Conjunctival scrape cytology findings in patients with chronic graft-versus-host disease following allogeneic bone marrow transplantation. Acta Cytol. 2010;54:272–276.
   PubMed Web of Science ®Google Scholar
• Nassiri N, Eslani M, Panahi N, et al. Ocular graft versus host disease following allogeneic stem cell transplantation: a review of current knowledge and recommendations. J Ophthalmic Vis Res. 2013;8:351–358.
   PubMedGoogle Scholar
• Hu B, Qiu Y, Hong J. Tear cytokine levels in the diagnosis and severity assessment of ocular chronic graft-versus-host disease(GVHD). Ocul Surf. 2020;18:298–304.
   Web of Science ®Google Scholar
• Nair S, Vanathi M, Mahapatra M, et al. Tear inflammatory mediators and protein in eyes of post allogenic hematopoeitic stem cell transplant patients. Ocul Surf. 2018;16:352–367.
   PubMed Web of Science ®Google Scholar
• de Almeida Borges D, Alborghetti MR. Franco Paes Leme A et al. Tear proteomic profile in three distinct ocular surface diseases: keratoconus, pterygium, and dry eye related to graft-versus-host disease. Clin Proteomics. 2020;17:42.
   Web of Science ®Google Scholar
• Berchicci L, Iuliano L, Miserocchi E, et al. Tear osmolarity in ocular graft-versus-host disease. Cornea. 2014;33:1252–1256.
   PubMed Web of Science ®Google Scholar
• West RH, Szer J, Pedersen JS. Ocular surface and lacrimal disturbances in chronic graft-versus-host disease: the role of conjunctival biopsy. Aust N Z J Ophthalmol. 1991;19:187–191.
   PubMedGoogle Scholar
• Wang Y, Ogawa Y, Dogru M, et al. Baseline profiles of ocular surface and tear dynamics after allogeneic hematopoietic stem cell transplantation in patients with or without chronic GVHD-related dry eye. Bone Marrow Transplant. 2010;45:1077–1083.
   PubMed Web of Science ®Google Scholar
• Giannaccare G, Bonifazi F, Sessa M, et al. Ocular surface analysis in hematological patients before and after allogeneic hematopoietic stem cell transplantation: implication for daily clinical practice. Eye (Lond). 2017;31:1417–1426.
   PubMed Web of Science ®Google Scholar
• Giannaccare G, Bonifazi F, Sebastiani S, et al. meibomian gland dropout in hematological patients before hematopoietic stem cell transplantation. Cornea. 2018;37:1264–1269.
   Web of Science ®Google Scholar
• Jeppesen H, Sengeløv H, Eriksson F, et al. Chronic ocular graft-versus-host disease after allogeneic haematopoietic stem cell transplantation in Denmark - factors associated with risks and rates in adults according to conditioning regimen. Bone Marrow Transplant. 2021;56:144–154.
   Google Scholar
• Pellegrini M, Giannaccare G, Bernabei F, et al. Longitudinal corneal endothelial cell changes in patients undergoing hematopoietic stem cell transplantation. In: Cornea; 2021;40(4):462–466.
   Google Scholar
• Schmid KE, Kornek GV, Scheithauer W, et al. Update on ocular complications of systemic cancer chemotherapy. Surv Ophthalmol. 2006;51:19–40.
   PubMed Web of Science ®Google Scholar
• Vishnevskia-Dai V, Rozner L, Berger R, et al. Ocular side effects of novel anti-cancer biological therapies. Sci Rep. 2021;11:787.
   Web of Science ®Google Scholar
• Kheirkhah A, Saboo US, Abud TB, et al. Reduced corneal endothelial cell density in patients with dry eye disease. Am J Ophthalmol. 2015;159:1022–1026.e1022.
   PubMed Web of Science ®Google Scholar
• Kheirkhah A, Satitpitakul V, Hamrah P, et al. Patients with dry eye disease and low subbasal nerve density are at high risk for accelerated corneal endothelial cell loss. Cornea. 2017;36:196–201.
   PubMed Web of Science ®Google Scholar
• Amparo F, Shikari H, Saboo U, et al. Corneal fluorescein staining and ocular symptoms but not Schirmer test are useful as indicators of response to treatment in chronic ocular GVHD. Ocul Surf. 2018;16:377–381.
   PubMed Web of Science ®Google Scholar
• Saboo US, Amparo F, Shikari H, et al. Prevalence of ocular hypertension and glaucoma in patients with chronic ocular graft-versus-host disease. Graefes Arch Clin Exp Ophthalmol. 2016;254:923–928.
   PubMed Web of Science ®Google Scholar
• Yu Q, Wang H, Zhang L, et al. Advances in the treatment of graft-versus-host disease with immunomodulatory cells. Int Immunopharmacol. 2021;92:107349.
   Web of Science ®Google Scholar
• Phulke S, Kaushik S, Kaur S, et al. Steroid-induced Glaucoma: an Avoidable Irreversible Blindness. J Curr Glaucoma Pract. 2017;11:67–72.
   PubMedGoogle Scholar
• Tahmaz V, Wiesen MHJ, Gehlsen U, et al. Detection of systemic immunosuppressants in autologous serum eye drops (ASED) in patients with severe chronic ocular graft versus host disease. Graefes Arch Clin Exp Ophthalmol. 2021;259:121–128.
   Web of Science ®Google Scholar
• Zeiser R, Blazar BR. Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation? Blood. 2016;127:3117–3126.
   PubMed Web of Science ®Google Scholar
• Negrin RS. Immune regulation in hematopoietic cell transplantation. Bone Marrow Transplant. 2019;54:765–768.
   Google Scholar
• Azari AA, Karadag R, Kanavi MR, et al. Safety and efficacy of autologous serum eye drop for treatment of dry eyes in graft-versus-host disease. Cutan Ocul Toxicol. 2017;36:152–156.
   PubMed Web of Science ®Google Scholar
• Anitua E, Muruzabal F, Tayebba A, et al. Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies. Acta Ophthalmol. 2015;93:e605–614.
   PubMed Web of Science ®Google Scholar
• Sanchez-Avila RM, Merayo-Lloves J, Muruzabal F, et al. Plasma rich in growth factors for the treatment of dry eye from patients with graft versus host diseases. Eur J Ophthalmol. 2020;30:94–103.
   PubMed Web of Science ®Google Scholar
• Xu M, Randleman JB, Chiu GB. Long-term descemetocele management with prosthetic replacement of the ocular surface ecosystem (PROSE) treatment. Eye Contact Lens. 2020;46:e7–e10.
   Web of Science ®Google Scholar
• Chiu GB, Theophanous C, Irvine JA. PROSE treatment in atypical ocular graft-versus-host disease. Optom Vis Sci. 2016;93:1444–1448.
   Google Scholar
• Markey KA, MacDonald KP, Hill GR. The biology of graft-versus-host disease: experimental systems instructing clinical practice. Blood. 2014;124:354–362.
   PubMed Web of Science ®Google Scholar
• Reddy P, Ferrara JLM. Mouse models of graft-versus-host disease. In: StemBook. Cambridge (MA): Harvard Stem Cell Institute; 2008. Copyright: © 2009 Pavan Reddy and James L.M. Ferrara., 2008–2009;Feb 28.
   Google Scholar
• Perez VL, Barsam A, Duffort S, et al. Novel scoring criteria for the evaluation of ocular graft-versus-host disease in a preclinical allogeneic hematopoietic stem cell transplantation animal model. Biol Blood Marrow Transplant. 2016;22:1765–1772.
   Google Scholar
• Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: i. The roles of minor H antigens and endotoxin. Blood. 1996;88:3230–3239.
   PubMed Web of Science ®Google Scholar
• Magone MT, Chan CC, Rizzo LV, et al. A novel murine model of allergic conjunctivitis. Clin Immunol Immunopathol. 1998;87:75–84.
   Google Scholar
• Poe JC, Jia W, Di Paolo JA, et al. SYK inhibitor entospletinib prevents ocular and skin GVHD in mice. In: JCI Insight. 2018;3(19):e122430.
   Google Scholar
• Pérez RL, Pérez-Simón JA, Caballero-Velazquez T, et al. Limbus damage in ocular graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17:270–273.
   PubMed Web of Science ®Google Scholar
• Sánchez-Abarca LI, Hernández-Galilea E, Lorenzo R, et al. Human bone marrow stromal cells differentiate into corneal tissue and prevent ocular graft-versus-host disease in mice. Cell Transplant. 2015;24:2423–2433.
   Web of Science ®Google Scholar
• Martínez-Carrasco R, Sánchez-Abarca LI, Nieto-Gómez C, et al. Assessment of dry eye in a GVHD murine model: approximation through tear osmolarity measurement. Exp Eye Res. 2017;154:64–69.
   Web of Science ®Google Scholar
• Zhang Z, Yang WZ, Zhu ZZ, et al. Therapeutic effects of topical doxycycline in a benzalkonium chloride-induced mouse dry eye model. Invest Ophthalmol Vis Sci. 2014;55:2963–2974.
   PubMed Web of Science ®Google Scholar
• Shamloo K, Barbarino A, Alfuraih S, et al. Graft versus host disease-associated dry eye: role of ocular surface mucins and the effect of rebamipide, a mucin secretagogue. Invest Ophthalmol Vis Sci. 2019;60:4511–4519.
   Web of Science ®Google Scholar
• Herretes S, Ross DB, Duffort S, et al. Recruitment of donor t cells to the eyes during ocular GVHD in recipients of MHC-matched allogeneic hematopoietic stem cell transplants. Invest Ophthalmol Vis Sci. 2015;56:2348–2357.
   Web of Science ®Google Scholar
• Ogawa Y, He H, Mukai S, et al. Heavy chain-hyaluronan/pentraxin 3 from amniotic membrane suppresses inflammation and scarring in murine lacrimal gland and conjunctiva of chronic graft-versus-host disease. Sci Rep. 2017;7:42195.
   Web of Science ®Google Scholar
• Martínez-Carrasco R, Sánchez-Abarca LI, Nieto-Gómez C, et al. Subconjunctival injection of mesenchymal stromal cells protects the cornea in an experimental model of GVHD. Ocul Surf. 2019;17:285–294.
   PubMed Web of Science ®Google Scholar
• Yaguchi S, Ogawa Y, Shimmura S, et al. Angiotensin II type 1 receptor antagonist attenuates lacrimal gland, lung, and liver fibrosis in a murine model of chronic graft-versus-host disease. PLoS One. 2013;8:e64724.
   PubMed Web of Science ®Google Scholar
• Mukai S, Ogawa Y, Urano F, et al. Novel treatment of chronic graft-versus-host disease in mice using the ER stress reducer 4-phenylbutyric acid. Sci Rep. 2017;7:41939.
   Google Scholar
• Yamane M, Ogawa Y, Mukai S, et al. Functional role of lacrimal gland fibroblasts in a mouse model of chronic graft-versus-host disease. Cornea. 2018;37:102–108.
   Web of Science ®Google Scholar
• Li W, Cao T, Luo C, et al. Crosstalk between ER stress, NLRP3 inflammasome, and inflammation. Appl Microbiol Biotechnol. 2020;104:6129–6140.
   PubMed Web of Science ®Google Scholar
• Sprenkle NT, Sims SG, Sánchez CL, et al. Endoplasmic reticulum stress and inflammation in the central nervous system. Mol Neurodegener. 2017;12:42.
   PubMed Web of Science ®Google Scholar
• Ohigashi H, Hashimoto D, Hayase E, et al. Ocular instillation of vitamin A-coupled liposomes containing HSP47 siRNA ameliorates dry eye syndrome in chronic GVHD. Blood Adv. 2019;3:1003–1010.
   PubMed Web of Science ®Google Scholar
• Royer DJ, Echegaray-Mendez J, Lin L, et al. Complement and CD4(+) T cells drive context-specific corneal sensory neuropathy. In: Elife. 2019;15(8):e48378.
   Google Scholar
• He J, Ogawa Y, Mukai S, et al. In vivo confocal microscopy evaluation of ocular surface with graft-versus-host disease-related dry eye disease. Sci Rep. 2017;7:10720.
   PubMed Web of Science ®Google Scholar
• Stephens DN, McNamara NA. Altered mucin and glycoprotein expression in dry eye disease. Optom Vis Sci. 2015;92:931–938.
   Web of Science ®Google Scholar
• Zeiser R, Blazar BR. Acute graft-versus-host disease - biologic process, prevention, and therapy. N Engl J Med. 2017;377:2167–2179.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377:2565–2579.
   PubMed Web of Science ®Google Scholar